Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria~* Have a length of disease duration, from first symptom, of less than (\<) 10 years~* Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy~* Suboptimal disease control while on a DMT~* Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening~* For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug~Exclusion Criteria:~* Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)~* Inability to complete an Magnetic Resonance Imaging (MRI) procedure~* Known presence of other neurological disorders~* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study~* History or currently active primary or secondary immunodeficiency~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* History of opportunistic infections~* History or known presence of recurrent or chronic infection~* History of malignancy~* Congestive heart failure~* Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ocrelizumab (Type: EXPERIMENTAL): Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.

Based on this trial design, predict the completion outcome and termination type (if applicable).